Please select the option that best describes you:
Do you recommend adjustment of lung dose constraints in the setting of stage III lung cancer treated with definitive concurrent chemoradiation followed by planned consolidation immunotherapy?
Answer from: Radiation Oncologist at Academic Institution
No, the normal tissue constraints have not changed now that adjuvant durvalumab is the new standard of care. Of course we should always be trying to make our normal tissue dose constraints as low as possible, without underdosing the target. And we should probably assume that all patients are g...
Sign in or Register to read more
Answer from: Radiation Oncologist at Academic Institution
We are reviewing our internal results on the first cohort of patients to make it through 1 year of consolidation Durva in clinical practice to determine whether rates of pneumonitis are higher, and if so, whether dose adjustment is reasonable. We will also explore whether lower dose metrics (such as...
Answer from: Radiation Oncologist at Community Practice
Soon, all lung constraints for lung cancer radiotherapy will have to presume immunotherapy. In May 2019, probably the vast majority of our patients get started on it following thoracic radiotherapy.Also, it does get personal. I have a lady who finished 5940 cGy in 33 fractions for Stage IIIA Adenoca...